Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib (ABT-494) Open-Label Extension Study in Crohn's Disease
NCT02782663Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2016
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, open-label trial of upadacitinib in Crohn's disease (2 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants Achieving Endoscopic Remission at 12 months and Percentage of Participants Achieving Clinical Remission at 12 months. Started May 2016; status: completed.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02782663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782663.